CDC May Expand Hepatitis B Vaccination Recommendations

Purified Cortrophin Gel Approved
November 1, 2021
Dyanavel-XR-Approved-in-Tablet-Form
Dyanavel XR Approved in Tablet Form
November 5, 2021
Purified Cortrophin Gel Approved
November 1, 2021
Dyanavel-XR-Approved-in-Tablet-Form
Dyanavel XR Approved in Tablet Form
November 5, 2021

November 3, 2021 – The Advisory Committee on Immunization Practices (ACIP) for the U.S. Centers for Disease Control and Prevention (CDC) now recommends hepatitis B vaccination for all adults who are less than 60 years of age, regardless of the individual's risk for contracting the hepatitis B virus (HBV).

  • Spread through contact with HBV-contaminated blood or other bodily fluids, hepatitis B infection can cause severe, potentially fatal liver damage. It often causes no immediately noticeable symptoms, meaning people can be infected and spread HBV to others without knowing it.
  • Although the ACIP recommends HBV vaccination for all U.S. adults under 60 years of age, the decision will not become public policy unless signed by the director of the CDC.
  • Currently, the CDC recommends hepatitis B vaccines for all infants and unvaccinated individuals under 19 years of age, as well as certain individuals over 19 years of age considered to be at high risk of HBV infection such as (but not limited to) healthcare and public safety workers, certain international travelers, and individuals with certain health conditions.